Yield

Yield

On the framework's adjusted-FCF basis, Pfizer's yield is negative — about −4.5% on FY2025 figures, −5.2% on the three-year average — because a serial-acquisition habit (a five-year average near $14.7 billion a year: Seagen, Array, Biohaven, Metsera) exceeds the company's entire reported free cash flow of roughly $9 billion. Even ignoring acquisitions, reported FCF yields 6.4% at today's $140.8 billion market cap, below the 10% bar and below the 8–9% fortress floor. Consensus, measuring unadjusted FCF, sees more than 10% — the gap is the M&A the patent cliff keeps forcing.

The adjustment, line by line

The three inputs are all taken from the filed cash-flow statements. Reported FCF is operating cash flow less capital expenditure. Stock-based compensation is small for a company this size — under $1 billion a year. The decisive term is acquisitions: Pfizer paid $10.9 billion for Array in 2019 [1], roughly $23.0 billion across Biohaven, Arena, GBT and others in 2022, $43.4 billion for Seagen in 2023 [2], and $6.9 billion for Metsera in 2025 [3]. Averaged over any trailing five years, that lands between $13 billion and $15 billion of annual acquisition outflow.

Adjusted FCF = reported FCF − SBC − trailing 5-fiscal-year average of acquisitions of businesses, net of cash acquired; derived from company filings. Components: FY2025 10-K Consolidated Statements of Cash Flows [4]; FY2023 10-K [5]; FY2021 10-K [6].

The workings for FY2025: reported FCF of $9,075 million, less SBC of $799 million [7], less the FY2021–FY2025 acquisition average of $14,671 million (the mean of $0, $22,997, $43,430, $0 and $6,927 million), equals −$6,395 million. The fit_features file reports this line as not_computable because its input feed carried no SBC and treated acquisitions as zero — a material error for a company that has spent roughly $84 billion on acquisitions in seven years. The figures above rebuild the series directly from the filed statements; the correction is recorded in the data gaps below.

Seagen alone tells the story: a $44.2 billion purchase ($43.4 billion net of cash), funded largely by $30.8 billion of new long-term debt issued in 2023 [8]. The framework treats normalized M&A as a recurring claim on owner cash precisely because a company facing a patent cliff must keep buying assets to replace expiring revenue — which is exactly Pfizer's position.

The yield, three ways

Adjusted FCF divided by the current $140.8B market cap ($24.64 × 5,713M shares, 24 Jul 2026); derived from company filings and the price feed. Reported FCF yield shown for contrast.

Current adjusted yield is −$6,395 million on a $140.8 billion market cap, or −4.5%. The three-year average adjusted FCF of −$7,304 million gives −5.2%. Both sit below zero. Reported FCF yield — the number a screen would show — is 6.4% (FY2025) and has ranged 3.4% to 7.0% over the last three years. The company's own yield baseline distribution is not_computable on the adjusted basis: with adjusted FCF negative in each recent year, there is no positive baseline for a current level to be a jump from. The fortress signature Ruchir hunts — a stable ~3.5–4% name suddenly near 8–9% on a fear scare — does not appear here. What appears instead is a reported FCF yield that has been structurally lower since the COVID windfall unwound, not a stable series dislocating upward.

Which bar applies

The balance-sheet class the framework uses to pick the reference line is unknown in fit_features only because EBITDA was missing from its feed. Rebuilding it: FY2025 EBITDA is income from continuing operations before taxes of $7,520 million [9], plus depreciation and amortization of $6,592 million [10], plus net interest expense of $2,068 million [11], or $16,180 million.

Net debt = long-term debt $61,641M + current portion of long-term debt $2,997M − cash $1,142M; liquid investments = short-term $12,454M + long-term $1,621M; EBITDA $16,180M. Balance sheet [12]; interest [13].

Net debt of $63,496 million against $16,180 million of EBITDA is 3.9x [14] — above the framework's 3.0x threshold, so the rule classes it levered. Netting Pfizer's $14.1 billion of short- and long-term investments still leaves 3.0x, at the levered line. This is not a fortress: the fortress class needs net cash or net debt under 0.5x EBITDA, and Pfizer is six to eight times that. So the reference line the framework selects is the 25% levered bar, not the 10% moderate bar.

The distinction is moot for the verdict. At −4.5% adjusted, the yield clears neither the 25% levered bar nor even the most lenient 10% moderate line — the shortfall is not measured in basis points but in sign. And the levered exception (the framework tolerates leverage only when the yield is massive, the buyback habit is demonstrated over years, and FCF/revenue is not deteriorating) fails on every limb: the yield is negative, buybacks were zero in 2023, 2024 and 2025 while share count rose, and — as the Self-Help tab develops — capital allocation has pointed at debt paydown and the dividend, not repurchases.

Normalized mid-cycle yield

Pfizer is not a classic cyclical, but its cash flow is distorted by two things worth normalizing: the COVID windfall that inflated FY2021–FY2022 FCF (reported FCF of $29.9 billion and $26.0 billion on revenues of $73.6 billion and $91.8 billion) and the Seagen acquisition bulge that dominates the trailing five-year M&A average today. A skeptic can recompute the mid-cycle yield under two explicit assumptions.

Assumption one — acquisitions revert to bolt-on scale. If Pfizer honors its stated intent to pause large M&A and delever, and the trailing acquisition average falls toward a bolt-on ~$3–4 billion a year as Seagen rolls out of the five-year window (around 2028), then adjusted FCF ≈ $9.1B reported − $0.8B SBC − $3.5B acquisitions ≈ $4.8 billion, or a 3.4% yield. Better than negative, still a third of the 10% bar.

Assumption two — ignore acquisitions entirely. Treating all M&A as discretionary growth capital, the ceiling is reported FCF less SBC: $9.1B − $0.8B ≈ $8.3B, a 5.9% yield. This is the most generous number that can honestly be constructed, and it still sits below the 8–9% fortress floor and well below the 10% moderate bar — before any allowance for the 2026–2030 loss-of-exclusivity wave (Eliquis, Vyndaqel, Ibrance, Xeljanz) that consensus expects to lower, not raise, near-term revenue. On no defensible normalization does Pfizer reach the bar its balance sheet demands.

The consensus check

CapIQ consensus measures free cash flow on the vendor's standard basis — cash from operations less capital expenditure, with no deduction for acquisitions or SBC — so it is not comparable to Ruchir's adjusted number and runs far higher.

Consensus FCF (CapIQ, CFO − capex basis) divided by the current $140.8B market cap; from data/sp/estimates.json. Bar shown at 10%.

On its own basis, consensus clears the moderate bar comfortably: forward FCF of $20.6 billion (FY2026), $17.7 billion (FY2027) and $15.8 billion (FY2029) implies yields of 14.6%, 12.6% and 11.2% on today's market cap. Read literally, the sell side already agrees the cash yield is high and the buy side is merely fearful — the strong-setup reading. But the entire gap between that picture and the framework's −4.5% is the two adjustments consensus omits. Consensus forward FCF also averages roughly $18 billion, nearly double Pfizer's reported statutory FCF of ~$9 billion, because it normalizes away working-capital swings and one-off cash items. Subtract SBC and the ~$14 billion five-year M&A average — the cash Pfizer actually spends replacing patent-cliff revenue — and the forward yield goes negative on the same estimates. The consensus does not underwrite the framework's bar; it underwrites a different, gross definition of free cash flow.

FCF-to-revenue trend

Conversion has recovered off the 2023 trough but remains structurally below the pre-COVID level, and turns negative once the acquisition drag is included.

Reported FCF ÷ total revenues; derived from company filings. Total revenues from the FY2025 10-K Consolidated Statements of Operations [15]; FCF from the cash-flow statements.

Pre-COVID, Pfizer converted 26–29% of revenue to free cash (FY2019–FY2020). The COVID years spiked to 41% then fell back; FY2023 collapsed to 8% on COVID inventory write-offs and the Seagen close; FY2024–FY2025 recovered to 14–15% [16]. So on the reported line, conversion is stabilizing — but at roughly half the pre-COVID rate, which cuts against the flywheel. On the framework's adjusted basis, conversion is negative, because acquisitions consume more than the whole of free cash flow. One further stress point on the cash claim: FY2025 dividends paid of $9,771 million already slightly exceed reported FCF of $9,075 million, a 0.93x coverage ratio [17]; the ~7% dividend, not repurchases, is where owner cash is going. Its safety is developed in Self-Help.

What would change this read: a genuine multi-year pause in large acquisitions (which would let the trailing five-year average fall toward bolt-on scale and lift adjusted FCF toward the reported ~6% line), or a step-up in reported FCF back toward the ~$16–17 billion five-year rolling average that would push even the acquisition-adjusted number toward positive. Neither is visible in the current filings or the consensus path.